Lab Dom Introduces New Innovations in Peptide Therapy and Flagship Cell Therapy Brand at International Congress in Bangkok
BANGKOK, Jan. 19, 2012 /PRNewswire-Asia/ -- Laboratoires Dom AVMM (Suisse) Inc. (Lab Dom) -- a world-leading regenerative medicine and cellular therapy company specialising in precursor stem cell, organ-specific cell, placenta extract and botanical cell therapy products -- will be introducing its latest innovations in peptide therapy, as well as its flagship Swiss cell therapy brand, at the 2nd International Congress of Aesthetic Dermatology (ICAD) in Bangkok, Thailand.
"Lab Dom has always been a well-respected pioneer in this rapidly developing industry, constantly pushing the frontiers of modern regenerative medicine with thought-leading and practical solutions to combat aging and chronic degenerative diseases," said Mike Chan, co-founder and director of Lab Dom.
With cornerstone technologies, state-of-the-art Swiss research facilities, as well as a brilliant line-up of global experts in cellular biology, stem cell, biophysics and biochemistry, Lab Dom took on a strategic expansionary move in 2010 that emboldened the variegation of its product portfolio today: a joint-venture with the rapidly developing company Regenerative Medical Solutions (RMS) to establish a specialised research division, Lab RMS, focused on ground-breaking peptide research and product formulations to lead a re-evolution in medical breakthrough technologies.
Lab RMS is the first to pioneer and commercialize a bio-engineered myostatin inhibitor with a unique self-regulating mechanism, known as Myopep -- "The Myostatin Blocker". Myopep is a proprietary amino acid complex capable of inducing a pharmaceutical grade effect in human muscle and adipose fat function, specifically developed for application in aesthetic, sports and regenerative medicine.
Introduced by Lab RMS in 2012, Myopep has been sequenced, patented and clinically proven to enhance muscle glucose utilization and growth, while reducing the production of fat throughout the body.
"Given that the global fitness and weight management market is estimated to reach US$586 billion in 2014 (Note 1), we are confident that the time is right to establish a proprietary peptide-based biopharmaceutical innovation that serves as an integral part of the therapeutic care for type 2 diabetes-related weight issues, obesity-related weight loss, muscular enhancement and sports medical rehabilitation," continued Mike Chan.
The 2nd International Congress of Aesthetic Dermatology (ICAD) was selected by the company as the ideal platform to forge new business links with regional medical practitioners and aesthetic clinicians. Being held at the stunning Centara Grand and Bangkok Convention Centre from 19-21 January 2012, this event will witness the participation of over 80 global companies and approximately 1700 of the most prominent medical practitioners in the region.
Lab Dom's presentation on the subject of 'New Global Innovations in Anti-Aging Regenerative Medicine: Swiss Cell Therapy and Precursor Stem Cell Therapy' will be headlined by Lab Dom's senior medical consultant Prof. Dr. Richard DeAndrea, who is a champion of the multidisciplinary approach to regenerative medicine and a leading authority on the subject. Dr. Richard will be supported by Co-Founder and Director Mike Chan, CEO Michael Lodge and Chief of Business Development Ronald Tai in a series of specialised presentations on Myopep for muscle building and slimming, Precursor Stem Cell Therapy for the treatment of chronic degenerative diseases, and organ-specific Eco-Ultrafiltrates (Nano Cell Extracts) for the specific nourishment and reinvigoration of individual organs and tissues.
"Lab Dom's timely participation at ICAD 2012 signifies not only our unflagging effort to strengthen the company's leadership position in the global markets, but also the continuation of our global stakeholder campaign with a renewed vigour," said Michelle Wong, co-founder and director of Lab Dom.
The company's dynamic stakeholder campaign 'Change, with Lab Dom', launched in September 2011, culminated in great success as it welcomed a new batch of valued and influential international partners to join the company in an exciting phase of global expansion, following a successful series of six international events held at Paris, Beirut, Bali, Hong Kong, Kuwait and Las Vegas.
"We are in the business of providing the opportunity for change for humankind, and an opportunity to increase the quality of life itself. Join us in this incredibly dynamic phase of Lab Dom's evolution, to share the bounty of our science, and to grow with our new business."
For more information visit www.changewithlabdom.com
Note:
1. Global Weight Loss and Diet Management Market: Market Prospects
2009-2014, published by marketsandmarkets.com, July 2009
About Lab Dom
Laboratoires Dom AVMM (Suisse) Inc. (LabDom) is a Swiss held and globally headquartered regenerative medicine and cellular therapy company, with regional Asia-Pacific headquarters in Kota Kinabalu, Malaysia.
Founded in 1991 by entrepreneurial husband and wife team, Mike Chan and Michelle Wong, Lab Dom is a world-leader in precursor stem cell, placental extract, organ-specific and botanical cell product manufacturing and distribution, providing revitalisation therapies to combat aging and chronic degenerative diseases.
With state-of-the-art laboratories and highly professional medical staff based in Switzerland, as well as the European Union and Asia-Pacific, Lab Dom is committed to innovative research and development in the rapidly expanding fields of regenerative medicine and anti-aging cellular therapy fields.
Lab Dom is currently embarking on a dynamic global expansion phase, aimed at increasing its presence in China, the European Union, the Middle East as well as the North and South American markets.
www.labdom.com
For media inquiries contact:
Andrew Tham
Message Manager
Lab Dom
Tel: +60-16-8105490
Email: [email protected]
SOURCE: Laboratoires Dom AVMM (Suisse) Inc.